Get started
Author

Laurence Sanhès

Observed names: L Sanhes, L. Sanhes, L. Sanhès, Laurence Sanhes, Sanhes, L., Sanhes, Laurence
Observed institutions: Inserm, Centre Hospitalier Universitaire de Grenoble, Institut Gustave Roussy, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier de Perpignan, Centre Hospitalier Universitaire Amiens-Picardie, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier Universitaire de Nîmes, Hôtel-Dieu de Paris, Groupe Francophone des Myélodysplasies, Hôpital Saint-Louis, Hôpital NOVO, Institut pour l'avancée des biosciences, Hôpital Tenon, Université Paris Diderot, Recherche clinique appliquée à l'hématologie, Institut Universitaire d'Hématologie, Centre Hospitalier de Boulogne sur Mer
ORCID: 0000-0003-1207-7665
Observed ORCID: 0000-0003-1207-7665
OpenAlex ID: A5003273516
Treatment of Older Patients with Mantle-Cell Lymphoma
2012 · H.C. Kluin-Nelemans, E. Hoster, et al. · New England Journal of Medicine · 520
PDF
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study
2019 · Caroline Houillier, Luc Taillandier, et al. · Journal of Clinical Oncology · 287
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
2011 · Thorsten Braun, Raphael Itzykson, et al. · Blood · 200
PDF
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
2020 · Laetitia Vercellino, Anne-Segolene Cottereau, et al. · Blood · 186
Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial
2012 · Gandhi Damaj, Rémy Gressin, et al. · Journal of Clinical Oncology · 166
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
2010 · Sylvain Thepot, Raphael Itzykson, et al. · Blood · 157
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
2018 · Judith Trotman, Sally F Barrington, et al. · The Lancet Oncology · 152
PDF
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
2015 · A Toma, O Kosmider, et al. · Leukemia · 123
PDF
Incidence and prognostic value of respiratory events in acute leukemia
2004 · D Chaoui, O Legrand, et al. · Leukemia · 114
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study
2022 · Caroline Houillier, Sylvain Dureau, et al. · Journal of Clinical Oncology · 112
Good Syndrome: An Adult-Onset Immunodeficiency Remarkable for Its High Incidence of Invasive Infections and Autoimmune Complications
2015 · Marion Malphettes, Laurence Gérard, et al. · Clinical Infectious Diseases · 105
Survival Response to B-Cell Receptor Ligation Is Restricted to Progressive Chronic Lymphocytic Leukemia Cells Irrespective of Zap70 Expression
2006 · Pierre-Antoine Deglesne, Nathalie Chevallier, et al. · Cancer Research · 99
Multicenter Outbreak of Infections by Saprochaete clavata , an Unrecognized Opportunistic Fungal Pathogen
2014 · Sophie Vaux, Alexis Criscuolo, et al. · mBio · 93
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma
2020 · Jill Corre, Aurore Perrot, et al. · Blood · 91
Validation of the revised international prognostic scoring system ( IPSS ‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS ( EUMDS ) registry
2015 · Louise de Swart, Alex Smith, et al. · British Journal of Haematology · 91
PDF
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
2018 · Mohamad Mohty, Mohamad Mohty, et al. · Clinical Lymphoma Myeloma & Leukemia · 82
A P hase 2 study of L ‐asparaginase encapsulated in erythrocytes in elderly patients with P hiladelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL‐SA 2‐2008 study
2015 · Mathilde Hunault‐Berger, Thibaut Leguay, et al. · American Journal of Hematology · 79
PDF
A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL
2020 · Norbert Schmitz, Lorenz H Truemper, et al. · Blood · 69
PDF
Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l ‐asparaginase: The GRAALL experience
2015 · Marie‐Anne Couturier, Françoise Huguet, et al. · American Journal of Hematology · 68
PDF
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
2022 · Anaïs Schavgoulidze, Alexis Talbot, et al. · Blood · 65
PDF
A randomized phase II trial of azacitidine +/- epoetin- in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
2016 · S. Thepot, R. Ben Abdelali, et al. · Haematologica · 62
Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study
2015 · M. Cheminant, C. Derrieux, et al. · Haematologica · 58
Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency
2016 · Rémi Bertinchamp, Laurence Gérard, et al. · The Journal of Allergy and Clinical Immunology In Practice · 55
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
2019 · Marie Sébert, Aline Renneville, et al. · Haematologica · 51
PDF
Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)
2018 · Oliver G. Ottmann, Heike Pfeifer, et al. · Blood · 50
Works count: 127
Citation count: 3,790
H-index: 27
I10-index: 52
Year
Topic
Type